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Abstract Roux-en-Y gastric bypass (RYGBP) is the most
commonly performed type of bariatric surgery, which is
used in the treatment of obesity and type 2 diabetes. Recent
case reports and case series have described a rare
complication of RYGBP, status post-gastric-bypass hyper-
insulinemic hypoglycemia, which was mainly managed
successfully with pancreatectomy. In this letter, we describe
the first successful management of status post-gastric-
bypass hyperinsulinemic hypoglycemia with diazoxide.
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Case Report
Obesity and type 2 diabetes (T2D) represent major health
concerns in USA. Bariatric surgery seems to be a very
effective tool in management of these conditions [1].
Roux-en-Y gastric bypass (RYGBP) is the most common
bariatric procedure performed in the USA, with approxi-
mately 140,000 procedures done in 2005 [2]. Several case
reports and case series studies have described a rare but
extremely interesting complication of RYGBP, status post-
gastric-bypass hyperinsulinemic hypoglycemia [3–8]. In
almost all of these cases, successful management was
achieved with partial or total pancreatic resection.
The patient is a 52-year-old woman with a personal
medical history of obesity, T2D, and dyslipidemia, who
underwent a gastric bypass surgery 4 years ago. Her
preoperative weight was 377 lb with a body mass index
of 63. Her T2D was managed with metformin, glipizide,
pioglitazone, and acarbose and her blood glucose levels
were ranging from 118 to 189 with an HbA1c around
7.6–7.8%. One year after the surgery, her weight had
decreased to 229 lb and medications for T2D were
discontinued 3 months after surgery, as the patient became
normoglycemic without medications. One year ago, the
patient reported complaints regarding several episodes of
sweating, hunger, nervousness, and discomfort that had
been happening in the last 6 months about 2 h after a meal.
Her blood glucose levels, examined at these episodes
occurring postprandially, were as low as 29, 48, and
55 mg/dl. Her fasting blood glucose and insulin levels
were 82 mg/dl and 7 μU/ml, respectively; at 2 h status after
the glucose tolerance test, her blood glucose and insulin
levels were 55 mg/dl and 35 μU/ml, respectively. Comput-
ed tomography of the abdomen with contrast and octreotide
scan was negative for the presence of insulinoma, a well-
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Rome, Italydescribed cause of hypoglycemia. Dietary modifications
(i.e., frequent meals with low percentage of carbohydrates)
had failed to improve her symptoms and also caused an
unfavorable weight gain of 35 lb. Administration of
diazoxide 50 mg twice a day was sufficient to control her
symptoms and the patient remains symptom free 16 months
after the administration of diazoxide. Attempts to stop
diazoxide for at least 2 weeks resulted in the recurrence of
hypoglycemia episodes.
Post-gastric-bypass hyperinsulinemic hypoglycemia repre-
sents a rare complication of RYGBP and, as very few cases
havebeenreported, theappropriate treatmentofthiscondition
is unknown. Successful management of this condition has
been reported with dietary modifications [4, 5]. However,
there is a growing tendency to treat these patients with
pancreatic resection. Partial pancreatic resection (at least
75%) is often unsuccessful, necessitating a further total
pancreatic resection [6, 8]. The end result of this approach is
to cause iatrogenic diabetes, necessitating lifelong treatment
with insulin. Diazoxide has been used in the treatment of this
condition; however, the result has been up until today
unsatisfactory [6]. Diazoxide (a specific adenosine-
triphosphate-dependent potassium channel agonist of β cells)
has been used successfully in the treatment of a similar
condition in infants and children, the persistent hyper-
insulinemic hypoglycemia of infancy [9]. Although this
approach may not be always successful in the persistent
hyperinsulinemic hypoglycemia of infancy, the recommen-
ded treatment is pharmacotherapy first (either with diazo-
xide, somatostatin analogs, or calcium channel blockers) and,
if unsuccessful, the recommended treatment is surgery [9].
Recently, Moreira et al. reported the first successful case
of management of post-gastric-bypass hyperinsulinemic
hypoglycemia with verapamil and acarbose [10]. Others
have reported successful management of post-gastric-
bypass hyperinsulinemic hypoglycemia with dietary mod-
ifications [4, 5], raising the question of whether pancrea-
tectomy should be the first line of treatment. Our letter may
represent the second successful case using pharmacological
measures; however, it is the first case which describes a
successful outcome after 16 months of medical therapy
with diazoxide.
We would like to raise the following questions: is timing
of post-gastric-bypass hyperinsulinemic hypoglycemia
medical management relevant in order to obtain a positive
patient answer to treatment? Is it possible that if the patient
with post-gastric-bypass hyperinsulinemic hypoglycemia is
treated promptly with diazoxide, she or he will more likely
not need to undergo surgery? In other words, could a very
prompt medical treatment with diazoxide prevent the need
for surgery? And finally should pancreatectomy (either
partial or total) be the first treatment option in patients with
post-gastric-bypass hyperinsulinemic hypoglycemia?
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